Clinical features of ulcerative colitis and Crohn’s disease in St. Petersburg: experience of the city inflammatory bowel disease center

Yu. P. Uspenskiy; Успенский Ю. П.; S. V. Petrov; Петров С. В.; Yu. A. Fominykh; Фоминых Ю. А.; Sergey V. Ivanov; Иванов Сергей Витальевич; E. P. Lykova; Лыкова Е. П.

doi:10.18565/pharmateca.2024.1.32-40

Clinical features of ulcerative colitis and Crohn’s disease in St. Petersburg: experience of the city inflammatory bowel disease center

Авторлар: Uspenskiy Y.P.¹, Petrov S.V.², Fominykh Y.A.¹^,3, Ivanov S.V.¹^,3, Lykova E.P.²
Мекемелер:
1. St. Petersburg State Pediatric Medical University
2. Elizavetinskaya Hospital
3. Almazov National Medical Research Center
Шығарылым: Том 31, № 1 (2024)
Беттер: 32-40
Бөлім: Gastroenterology/hepatology
URL: https://journals.eco-vector.com/2073-4034/article/view/632209
DOI: https://doi.org/10.18565/pharmateca.2024.1.32-40
ID: 632209

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация
Толық мәтін
Авторлар туралы
Әдебиет тізімі
Қосымша файлдар
Статистика

Аннотация

Background. Inflammatory bowel diseases (IBDs) are a pressing problem in gastroenterology around the world due to a recurrent course, a pronounced decrease in quality of life, disabling complications and the difficulties of individual selection of therapy.

Objective. Clinical assessment of the course and treatment of IBD in a cohort of patients who were followed-up to the City IBD Center in Elizavetinskaya Hospital, St. Petersburg.

Methods. A cross-sectional sample study that included demographic and clinical data of 516 patients with IBD who visited a City IBD Center in 2020–2023 was conducted. This sample of patients was compared with a cohort of 1078 patients with IBD who received treatment in 42 clinics and 6 hospitals in St. Petersburg in 2018–2020.

Results. Systematic differences between the cohort of patients who received treatment in the City IBD Center and the cohort of patients with this pathology who received drug treatment in medical institutions in the city healthcare system were identified. In the City IBD Center, patients with complicated, moderate and severe course of the disease were mainly followed-up. In the structure of extraintestinal manifestations, peripheral arthropathy and damage to the mucous membranes were in the lead, and in the structure of identified complications – anemia and protein-energy deficiency. Distinctive features of drug therapy prescribed for the management of patients at the IBD Center were the widespread use of genetically engineered biological therapy, as well as the active use of immunosuppressants in the treatment of Crohn’s disease, which is fully consistent with current clinical recommendations. Conclusion. In the City IBD Centers within the framework of the St. Petersburg City Healthcare System, the most clinically difficult patients with ulcerative colitis and Crohn’s disease are followed-up and receive the necessary treatment. The importance of City IBD Centers in providing specialized gastroenterological care to patients of this category in St. Petersburg will increase in the coming years.

Негізгі сөздер

inflammatory bowel diseases, ulcerative colitis, Crohn’s disease, city IBD center, complications, extraintestinal manifestations, St. Petersburg IBD Register

Толық мәтін

Cand. Sci. (Med.), Associate Professor at the Department of Faculty Therapy n.a. prof. V.A. Valdman, Associate Professor at the Department of Propaedeutics of Internal Diseases with a Clinic

Ресей, St. Petersburg; St. Petersburg

E. Lykova

Elizavetinskaya Hospital

Email: ivanov.sv@mail.ru
Ресей, St. Petersburg

Әдебиет тізімі

Шелыгин Ю.А. и др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10–49. [Shely-gin Yu.A. and others. Clinical recommendations. Crohn’s disease (K50), adults. Coloproctology. 2023;22(3):10–49. (In Russ.)]. doi: 10.33878/2073-7556-2023- 22-3-10-49.
Шелыгин Ю.А. и др. Клинические рекомендации. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. [Shely-gin Yu.A. and others. Clinical recommendations. Ulcerative colitis (K51), adults. Coloproctology. 2023;22(1):10–44. (In Russ.)]. doi: 10.33878/2073-7556-2023- 22-1-10-44.
Успенский Ю.П., Иванов С.В., Фоминых Ю.А., Галагудза М.М. Клиническая характеристика воспалительных заболеваний кишечника в Санкт-Петербурге и особенности использования базисной терапии в системе городского здравоохранения: результаты одномоментного эпидемиологического исследования. Экспериментальная и клиническая гастроэнтерология. 2021;190(6):29–39. [Uspensky Yu.P., Ivanov S.V., Fominykh Yu.A., Galagudza M.M. Clinical characteristics of inflammatory bowel diseases in St. Petersburg and features of the use of basic therapy in the city healthcare system: results of a cross-sectional epidemiological study. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021;190(6):29–39. (In Russ.)]. doi: 10.31146/1682-8658-ecg-190-6-29-39.
Успенский Ю.П., Шабров А.В., Иванов С.В. и др. Базисная терапия воспалительных заболеваний кишечника в Санкт-Петербурге: результаты многоцентрового исследования. Экспериментальная и клиническая гастроэнтерология. 2022;198(2):64–76. [Uspen-sky Yu.P., Shabrov A.V., Ivanov S.V. and others. Basic therapy of inflammatory bowel diseases in St. Petersburg: results of a multicenter study. Eksperimental’naya i klinicheskaya gastroenterologiya. 2022;198(2):64–76. (In Russ.)]. doi: 10.31146/1682-8658-ecg-198-2-64-76.
Успенский Ю.П., Сарана А.М., Мелентьева Л.Н. и др. Первый региональный регистр пациентов с воспалительными заболеваниями кишечника на базе региональной информационной системы здравоохранения Санкт-Петербурга: принципы функционирования, результаты апробации, план развития. [Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023;33(4):38–57. Uspensky Yu.P., Sarana A.M., Melentyeva L.N. et al. The first regional register of patients with inflammatory bowel diseases based on the regional health information system of St. Petersburg: principles of operation, testing results, development plan. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2023;33(4):38–57. (In Russ.)]. doi: 10.22416/1382-4376-2023-33-4-38-57.
Успенский Ю.П., Иванов С.В., Фоминых Ю.А. и др. Прогнозирование развития жизнеугрожающих осложнений воспалительных заболеваний кишечника с использованием нейронных сетей: инструменты для практического здравоохранения. Экспериментальная и клиническая гастроэнтерология. 2023;217(9):20–33. [Uspensky Yu.P., Ivanov S.V., Fominykh Yu.A. et al. Prediction of the development of life-threatening complications of inflammatory bowel diseases using neural networks: tools for practical healthcare. Eksperimental’naya i klinicheskaya gastroenterologiya. 2023;217(9):20–33. doi: 10.31146/1682-8658-ecg-217-9-20-33.
Torres J., Bonovas S., Doherty G., et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180.
Turner D., Ricciuto A., Lewis A., et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterol. 2021;160(5):1570–83. doi: 10.1053/j.gastro.2020.12.031.
Paridaens K., Fullarton J.R., Travis S.P.L. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin. 2021;37(11):1891–900. doi: 10.1080/03007995.2021.1968813.
Jesionowski M., Rydzewska G., Danese S., Paridaens K. Assessment of the effectiveness of Budesonide MMX® for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study. Gastroenterol Rev. 2023;18(2):154–60. doi: 10.5114/pg.2023.129413.
Kearns J., Scullion L., Masterson C., et al. A real-world, observational, multi-centre study comparing Budesonide MMX with Prednisolone in patients with mild to moderate ulcerative colitis. Gut. 2023;72(Suppl. 2):A97–8. doi: 10.1136/gutjnl-2023-BSG.158.